BB Good human data, but mixed outcomes or surrogate markers. How we grade →RCT · 104 kidney transplant recipients
Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study
X Wu, Q Li, H Xin, A Yu, M Zhong. European Journal of Clinical Pharmacology. 2005.
Bottom line: In kidney transplant recipients, adding berberine raised blood levels of the immunosuppressant cyclosporine by about 29% to 35%, a clinically relevant drug interaction.
- In plain language
- In this randomized trial, 104 kidney transplant recipients taking the immunosuppressant cyclosporine either added berberine (200 mg three times a day) or did not, for 3 months. Cyclosporine trough levels rose in both groups, but at the end they were 29.3% higher with berberine than without it, with no significant effects on liver or kidney function. In a separate pharmacokinetic study of six recipients given berberine for 12 days, total cyclosporine exposure (AUC) rose 34.5% and clearance fell 40.4%. The authors attribute the interaction mainly to berberine inhibiting the enzyme CYP3A4.
- Limits
- This was a single-center trial and was not blinded. The detailed pharmacokinetic analysis included only six patients, and results apply to kidney transplant recipients on cyclosporine.
- Which of our grades it feeds
- CC Small or few human trials. Promising, not proven. How we grade →Science summary: Berberine dose, side effects and drug interactions: what the trials used and who should skip it
- CC Small or few human trials. Promising, not proven. How we grade →Science summary: Berberine and glucose metabolism
- CC Small or few human trials. Promising, not proven. How we grade →Ratings card: Berberine HCl: Healthy glucose metabolism
- Source
- doi.org/10.1007/s00228-005-0952-3 · PubMed 16133554
Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. Reviewed . We sell some of what we grade.